Abstract
Nanotechnology has been the last frontier in the diagnoses and treatment of many diseases, especially in oncology. The use of nanoparticles of radiopharmaceuticals may represent the future of Nuclear Medicine. In this study we developed, characterized and tested polymeric nanoparticles of FMISO (fluoromisonidazole) in a dynamic study of biodistribution. The results of the development as characterization showed that nanoparticles were well obtained with a size range of 300- 500nm and a spherical shape.
Keywords: Radiopharmaceuticals, Oncology, Nuclear Medicine, Hypoxia, Predictive.
Current Radiopharmaceuticals
Title:Polymeric Nanoparticles of FMISO: Are Nano-Radiopharmaceuticals Better Than Conventional Ones?
Volume: 5 Issue: 4
Author(s): Marta de Souza Albernaz, Beatriz Ferreira de Carvalho Patricio, Gilberto Weissmuller, Franceline Reynaud, Tom CH Adamsen and Ralph Santos-Oliveira
Affiliation:
Keywords: Radiopharmaceuticals, Oncology, Nuclear Medicine, Hypoxia, Predictive.
Abstract: Nanotechnology has been the last frontier in the diagnoses and treatment of many diseases, especially in oncology. The use of nanoparticles of radiopharmaceuticals may represent the future of Nuclear Medicine. In this study we developed, characterized and tested polymeric nanoparticles of FMISO (fluoromisonidazole) in a dynamic study of biodistribution. The results of the development as characterization showed that nanoparticles were well obtained with a size range of 300- 500nm and a spherical shape.
Export Options
About this article
Cite this article as:
de Souza Albernaz Marta, Ferreira de Carvalho Patricio Beatriz, Weissmuller Gilberto, Reynaud Franceline, CH Adamsen Tom and Santos-Oliveira Ralph, Polymeric Nanoparticles of FMISO: Are Nano-Radiopharmaceuticals Better Than Conventional Ones?, Current Radiopharmaceuticals 2012; 5 (4) . https://dx.doi.org/10.2174/1874471011205040336
DOI https://dx.doi.org/10.2174/1874471011205040336 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plant Extracts as a Natural Source of Bioactive Compounds and Potential Remedy for the Treatment of Certain Skin Diseases
Current Pharmaceutical Design Editorial: Towards MiRNA Based Therapeutics for Lung Cancer
Current Pharmaceutical Design Oxidative stress in carcinogenesis: new synthetic compounds with dual effects upon free radicals and cancer.
Current Medicinal Chemistry How Much Gets there and What Does it Do?: The Need for Better Pharmacokinetic and Pharmacodynamic Endpoints in Contemporary Drug Discovery and Development
Current Pharmaceutical Design The Applicability of mTOR Inhibition in Solid Tumors
Current Cancer Drug Targets Bergamot Juice Extract Inhibits Proliferation by Inducing Apoptosis in Human Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization
Anti-Cancer Agents in Medicinal Chemistry Rational Design of CPP-based Drug Delivery Systems: Considerations from Pharmacokinetics
Current Pharmaceutical Biotechnology Recent Developments in the Third Generation Inhibitors of Bcr-Abl for Overriding T315I Mutation
Current Medicinal Chemistry Development of Extracellular Signal-Regulated Kinase Inhibitors
Current Topics in Medicinal Chemistry Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design Chemopreventive Effects of Conjugated Linolenic Acids (CLN) Occurring in Plant Seed Oils
Current Nutrition & Food Science Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery
Current Pharmaceutical Design Cyclophosphamide: Time to Say Goodnight and Goodbye?
Current Rheumatology Reviews Effects of Polymorphisms of the CYP450 Enzyme Genes on Estrogen Status and the Risk for Osteoporosis
Current Pharmacogenomics Chemical Modifications of Two Polysaccharides as Drug Carriers
Current Organic Synthesis Choosing between Targeted Therapies for Rheumatoid Arthritis Patients: The Oncology Perspective
Current Rheumatology Reviews Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases
Current Medicinal Chemistry The Role of Metabolism in Toxicity of Polycyclic Aromatic Hydrocarbons and their Non-genotoxic Modes of Action
Current Drug Metabolism Novel and Emerging Drugs for Chronic Lymphocytic Leukemia
Current Cancer Drug Targets